News
Company News: VesselSens: First Research Group at Life Science Inkubator Bonn to Receive Funding from EXIST Program
— Preclinical development of an implantable sensor system for the wireless detection of vascular constriction funded with EUR 1 mn
VesselSens is the first research group based at Life Science Inkubator (LSI) Bonn, Germany, to receive funding from the EXIST Transfer of Research Program by Germany’s Federal Ministry of Economic Affairs and Energy (BMWi). VesselSens is developing novel sensor technologies for the early, non-invasive detection of a recurrent vascular constriction at the site of an implanted stent (restenosis). Read more…
Company News: Clickmer Systems Receives EUR 1.73 Million for the Development of Novel Synthetic Detection Reagents for Medical Research and Diagnostics
— Supported by Life Science Inkubator (LSI) Bonn
— Alternative to antibody-based detection with improved reproducibility and reliability
Clickmer Systems, a spin-off from the University of Bonn, Germany, today announced its incubation at Life Science Inkubator (LSI) Bonn. With the incubation, the project team has not only secured funds totaling EUR 1.73 million from the German Ministry of Education and Research (BMBF), but also gains access to the LSI infrastructure and support from seasoned life science professionals in LSI’s network. This will allow the team to further advance its technology and build an attractive product pipeline. Read more…
Company News: New Data on Curetis’ Unyvero LRT Panel for Pneumonia to be Presented at ASM Microbe 2019
– Several scientific conference contributions outline benefits of U.S. FDA-cleared Unyvero LRT Application Cartridge in both endotracheal aspirate and bronchoalveolar lavage samples
– Study shows that Unyvero LRT has potential to support antibiotic stewardship and may reduce time to actionable clinical results by more than two days
Curetis N.V. (the “Company” and, together with Curetis GmbH and Curetis USA Inc. “Curetis”), a developer of next-level molecular diagnostic solutions, today announced that new data on its Unyvero System and LRT Application Cartridge for pneumonia will be presented at the upcoming ASM Microbe Conference, June 20-24, 2019, in San Francisco, CA, USA. Read more…
Company News: Curetis Reports Positive Results from Clinical Validation Study for U.S. FDA 510(k) Submission of Unyvero LRT for BAL Samples
– Test shows overall weighted average sensitivity of 90.1% (94.7%) and overall weighted average specificity of 98.4% (97.9%) in prospective (retrospective) sample cohort
– U.S. FDA 510(k) submission for Unyvero LRT BAL Application Cartridge in preparation
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis”), a developer of next-level molecular diagnostic solutions, today announced key data from its successfully completed Unyvero LRT clinical performance evaluation study for BAL samples. Read more…